Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application [PDF]
Journal of Medicinal Chemistry, 2019 The use of kinase-directed precision medicine has been heavily pursued since the discovery and development of imatinib. Annually, it is estimated that around ∼20 000 new cases of tropomyosin receptor kinase (TRK) cancers are diagnosed, with the majority ...
Naresh Gunaganti +2 more
exaly +7 more sources
Withdrawal pain following patients discontinuing Trk inhibitors [PDF]
Journal of Oncology Pharmacy PracticeOBJECTIVE: This article aims to expand on the existing literature regarding the incidence of withdrawal pain following discontinuation of Trk inhibitors and to explore strategies that mitigate this withdrawal pain.
Hyunseok Kang +2 more
exaly +4 more sources
Molecules, 2022 The tropomyosin receptor kinases (TRKs) have been validated as effective targets in anticancer drug discovery. Two first-generation TRK inhibitors have been approved into market and displayed an encouraging therapeutic response in cancer patients ...
Jie Wang +11 more
doaj +2 more sources
Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Pediatric Patients [PDF]
Current Oncology, 2021 Neurotrophic tyrosine receptor kinase gene fusions (NTRK) are oncogenic drivers present at a low frequency in most tumour types (80%) in a small number of rare tumours (e.g., infantile fibrosarcoma [IFS]) and considered mutually exclusive with other ...
Sébastien Perreault +10 more
doaj +2 more sources
Detection of NTRK Fusions and TRK Expression and Performance of pan-TRK Immunohistochemistry in Routine Diagnostics: Results from a Nationwide Community-Based Cohort [PDF]
Diagnostics, 2022 Gene fusions involving NTRK1, NTRK2, and NTRK3 are rare drivers of cancer that can be targeted with histology-agnostic inhibitors. This study aimed to determine the nationwide landscape of NTRK/TRK testing in the Netherlands and the usage of pan-TRK ...
Bart Koopman +6 more
doaj +3 more sources
Endocrine Late Effects of Targeted and Immune-Based Therapies in Pediatric Oncology [PDF]
CellsAdvances in pediatric oncology have markedly improved survival, shifting attention toward long-term treatment-related morbidity. Targeted agents and immune-based therapies are now widely used across pediatric malignancies and selected non-malignant ...
Vittorio Ferrari +6 more
doaj +2 more sources
Paediatric and Adult Solid Tumours Exhibiting NTRK Gene Fusions in Australia, 2020–2044: A Population‐Based Statistical Modelling Study [PDF]
Cancer MedicineBackground TRK inhibitors targeting NTRK fusion‐positive cancers have the potential to improve patient outcomes, but also have high costs. We report the first long‐term projections of cancer prevalence associated with NTRK gene fusions in Australia, to ...
Qingwei Luo +5 more
doaj +2 more sources
Tracking Down Response and Resistance to TRK Inhibitors. [PDF]
Cancer Discov, 2016 Two recent studies validate the LMNA-NTRK1 fusion as an oncogenic driver and therapeutic target of TRK inhibitors. The LMNA-NTRK1 fusion occurs at low frequency across multiple tumor types.
Okimoto RA, Bivona TG.
europepmc +2 more sources
TRK Inhibitors in Adult and Pediatric High-Grade Gliomas: A Systematic Review and Individual Participant Data Meta-Analysis. [PDF]
Cancers (Basel)Background: High-grade glioma (HGG) is the most common primary malignant brain tumor, with peak incidence in the fifth and sixth decades of life. Although HGG is rare in children, the prognosis remains poor, with a median overall survival (OS) of less ...
Rizzaro MD +7 more
europepmc +2 more sources
NTRK Fusion in Non-Small Cell Lung Cancer: Diagnosis, Therapy, and TRK Inhibitor Resistance
Frontiers in Oncology, 2022 Neurotrophic tropomyosin receptor kinase (NTRK) gene fusion has been identified as an oncogenic driver of various solid tumors, and it is rare in non-smalll cell lung cancer (NSCLC) with a frequency of approximately less than 1%.
Fangfang Liu +5 more
doaj +1 more source